Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography.

• Status: Recruiting
• Trial end date: 2024-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Does Ketamine-Midazolam have a better efficacy and safety profile compared to Midazolam - Pethidine in Endoscopic Retrograde Cholangiopancreatography (ERCP)?

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National University of Malaysia
• Treatments: Ketamine; Meperidine; Midazolam

Criteria

Inclusion Criteria:

• Adults > 18 years old which able to give valid consent

• Patient planned for ERCP (either emergency or elective)

• American Society of Anaesthesiologist (ASA) score of I-III

Exclusion Criteria:

• Known hypersensitivity towards Ketamine or Midazolam

• Increased intracranial pressure, acute stroke (<3 months), intracranial haemorrhage (<3 months)

• Severe hypertension (BP>170/110) and tachycardia (Heart rate >110)

• Acute myocardial infarction, acute coronary syndrome (< 6 months)

• Tachyarrhythmia

• Pregnancy

• Intravenous drug user (IVDU) or substance abuse patient

• History of hallucination

• Child's Pugh class C